Neuron BioPharma presents new advances in our understanding of the relationship between cholesterol and neurodegenerative diseases.
Neuron BioPharma, a division of the company Neuron Bio, has published new results in the international scientific journal PLOS One which link cholesterol levels in blood and the development of neurodegenerative diseases. Research into Alzheimer’s disease is the priority aim of this division, which focuses mainly on understanding the involvement of cholesterol regulation in the brain during the progress of this kind of disease.
The paper entitled, “ApoB100/LDLR-/- Hypercholesterolaemic Mice as a model for Mild Cognitive Impairment and Neuronal Damage”, shows how transgenic mice with high levels of cholesterol in the blood (ApoB100/LDLR-/-) used in research as an animal model for the study of inherited hypercholesteremia show neuronal damage at an early age similar to that in much older non-transgenic mice, which demonstrates the influence of cholesterol on the processes of cognitive deterioration.
In summary, the results show that hypercholesteremia can be used as a key biomarker for monitoring mild cognitive impairment (MCI) and also shows that these transgenic mice can be used as a model for cognitive and psychomotor deterioration.
PLOS One, the journal in which these results have been published, is one of the most prestigious on-line scientific journals, edited by The Public Library of Science (PLoS), a non-profit organisation for scientists and professionals in the field of medicine.